| Literature DB >> 36071944 |
Mateusz Grajek1, Karolina Krupa-Kotara2, Agnieszka Białek-Dratwa3, Karolina Sobczyk4, Martina Grot1, Oskar Kowalski3, Wiktoria Staśkiewicz5.
Abstract
Applied psychopharmacotherapy and psychotherapy do not always bring the expected results in the treatment of mental disorders. As a result, other interventions are receiving increasing attention. In recent years, there has been a surge in research on the effects of nutrition on mental status, which may be an important aspect of the prevention of many mental disorders and, at the same time, may lead to a reduction in the proportion of people with mental disorders. This review aims to answer whether and to what extent lifestyle and related nutrition affect mental health and whether there is scientific evidence supporting a link between diet and mental health. A review of the scientific evidence was conducted based on the available literature by typing in phrases related to nutrition and mental health using the methodological tool of the PubMed database. The literature search yielded 3,473 records, from which 356 sources directly related to the topic of the study were selected, and then those with the highest scientific value were selected according to bibliometric impact factors. In the context of current changes, urbanization, globalization, including the food industry, and changes in people's lifestyles and eating habits, the correlations between these phenomena and their impact on mental state become important. Knowledge of these correlations creates potential opportunities to implement new effective dietary, pharmacological, therapeutic, and above all preventive interventions. The highest therapeutic potential is seen in the rational diet, physical activity, use of psychobiotics, and consumption of antioxidants. Research also shows that there are nutritional interventions that have psychoprotective potential.Entities:
Keywords: diet; eating behavior; mental health; nutrition; psychology of food
Year: 2022 PMID: 36071944 PMCID: PMC9441951 DOI: 10.3389/fnut.2022.943998
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
FIGURE 1A flowchart of how to proceed in selecting bibliographic sources.
Review of selected studies on the psychoprotective effect of probiotics.
| Source | Sample | Bioactive ingredient | Results or conclusions |
| Gazerani ( | Review article – group struggling with migraine headaches | Folate in the form of folic acid – B9 | Addition of a methyl group to DNA methyltransferase during the DNA methylation process and adequate serum homocysteine secretion levels prevent migraine headaches |
| Cater et al. ( | Review article – neurotherapeutic properties among healthy human populations and newborns | Docosahexaenoic acid – omega-3 | Stimulates neurotransmission and development of the cerebral cortex |
| Parikh et al. ( | Review article – among a population of people with nervous system conditions – depression and newborns with encephalopathy | Alpha-lipoic acid, lignans, soluble fiber, phytoestrogen – secoisolariciresinol diglucoside | Development and size of cortical cells in the prenatal and postnatal periods. Neuromodulates cognitive-behavioral behavior. Prevention against depressive symptoms in offspring and hypoxic-ischemic encephalopathy among newborns. Reduced oxidative stress parameters in the oxidation process reducing inflammation within the nervous system |
| Park et al. ( | Depressed patients. Blinded randomized study. | Flavonoids | Improving brain-derived neurotrophic parameter (BDNF), reducing symptoms in the pathomechanism of depression. PSD-95 protein expression affects dysfunction within synapses and neurons |
| Mittal et al. ( | Review article – reduction in symptoms and progression of Parkinson’s disease | Exogenous amino acid – tryptophan | Metabolic transformations to the starting compound serotonin allow to achieve regulation of the diurnal rhythm, emotional state. Participation in the metabolism of catecholamines regulating processes at the level of the brain-gut axis. Prevention in the pathomechanism of Parkinson’s disease |
| Fernández et al. ( | Review studies, meta-analysis of studies. Improvement of neuronal and cognitive impairment in patients with Parkinson’s disease, schizophrenia, depression | Magnesium calcium, selenium, zinc, manganese, copper, antioxidants – vitamin D, E, C, carotenoids | Reducing the mechanism of oxidative stress achieving systemic balance consequently the absence of chronic inflammation along with a decrease in CRP, IL-6, WBC indices and somato-psychological symptoms in a depressed state. |
| Godos et al. ( | Review studies, meta-analysis of studies | Complex carbohydrates, eicosapentaenoic acid, amino acid – glycine, polyphenols, anthocyanins | Regulation of neuromodulator and neurotransmitter expression. Reduced activation of the hypothalamic-pituitary-adrenal axis under the influence of lower levels of endogenous stress – lower corticosterone concentrations. Proper insulin secretion and glucose ejection into cells – adequate GLUT receptor functionality. Modulation of the processes of neurogenesis, synaptic plasticity and activation of microglia in the central nervous system. Prevention of inflammation, neurodegenerative changes through inactivation of the process of oxidation of the LDL fraction, lipid peroxidation and activation of the enzymes catalase and superoxide dismutase |
Source: Own compilation based on literature review.
Review of selected studies on the psychoprotective effects of substances contained in food.
| Source | Sample | Preparation (Bacterial strain) | Results or conclusions |
|
| |||
| Diop et al. ( | Healthy adults. Blinded, randomized study. Duration – 12 weeks | Lactobacillus acidophilus Rosell-52, Bifidobacterium longum Rosell-175 (3 × 109 CFU/day) | Probiotic therapy has been shown for the first time to reduce gastrointestinal complaints in people under stress: |
| Messaoudi et al. ( | Healthy adults. Double-blind, randomized study. | Lactobacillus helveticus R0052, Bifidobacterium longum R0175 (3 × 109 CFU/day) | The first study to show that administration of a psychobiotic alleviates stress-induced psychiatric symptoms: |
|
| |||
| Wallace et al. ( | Depressed patients who were not taking antidepressants. Blinded, randomized study. | Lactobacillus helveticus R0052, Bifidobacterium longum R0175 (6 × 109 CFU/day) | After 4 weeks of taking the psychobiotic, there was a reduction in scores on the assessment scales: |
| Kazemi et al. ( | Depressed patients who were taking antidepressants (sertaline, escitalopram, fluixetine, or amitriptyline). RCT study. | Lactobacillus helveticus, Bifidobacterium longum | • Decreased scores on the Beck Depression Scale (compared to the group taking placebo or the prebiotic galactooligosaccharide). |
| Rudzki et al. ( | Patients with depression. Double-blind RCT study. | SSRI + Lactobacillus plantarum 299v (10 × 109 CFU/day) | Augmenting SSRI treatment with probiotic bacteria Lactobacillus Plantarum 299v improved cognitive performance and reduced KYN levels in MDD patients. Reduced KYN levels may have contributed to cognitive improvement in the LP299v group compared to the placebo group |
| Wallace et al. ( | Patients with depression. Double-blind RCT study. | Lactobacillus helveticus Rosell-52, Bifidobacterium Longum Rosell-175 (3 × 109 CFU) | Probiotics have a role in alleviating symptoms of depression |
| Heidarzadeh-Rad et al. ( | Patients with depression. RCT | Lactobacillus helveticus Rosell-52, Bifidobacterium Longum Rosell-175 (≥ 10 × 109 CFU) | Eight-week supplementation in depressed patients improved depressive symptoms, likely by increasing BDNF levels |
|
| |||
| Agahi et al. ( | Alzheimer’s patients. Double-blind RCT study. | Lactobacillus fermentum, Lactobacillus plantarum, Bifidobacterium lactis, Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum (3 × 109 CFU/day) | Cognitive and biochemical indications in patients with severe AD are insensitive to probiotic supplementation. Therefore, in addition to the composition and dose of probiotic bacteria, the severity of the disease and the timing of administration profoundly affect treatment outcomes. |
| Akbari et al. ( | Alzheimer’s patients. Double-blind RCT study. | 200 mL/day of milk product containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum (2 × 109 CFU/day) | Probiotic treatment had no significant effect on biomarkers of oxidative stress and inflammation, fasting glucose and other lipid profiles. The study showed that probiotic consumption for 12 weeks had a positive effect on cognitive function and some metabolic statuses in AD patients |
| Tamtaji et al. ( | Alzheimer’s patients. Double-blind RCT study. | Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum (6 × 109 CFU/day) + 200 mcg selenium | Co-supplementation of probiotics and selenium for 12 weeks in AD patients improved cognitive function and some metabolic profiles |
|
| |||
| Wallis et al. ( | Patients with Chronic Fatigue Syndrome. Open-label study. | Alternating antibiotic and probiotic therapy: Erythromycin + Lactobacillus rhamnosus (2.5 × 1010 CFU/day), Bifidobacterium lactis (1.5 × 1010CFU/day), Bifidobacterium breve (5 × 106 CFU/day), Bifidobacterium longum (5 × 106 CFU/day) | Specific microorganisms interact with some ME/CFS symptoms and offer the promise of therapeutic potential targeting intestinal dysbiosis in this population |
|
| |||
| Hwang et al. ( | Patients with mild cognitive impairment. Double-blind RCT study. | Lactobacillus plantarum C29 (1.25 × 1010 CFU/day) + powdered fermented soybeans (DW2009) | DW2009 can be safely administered to improve cognitive function in people with MCI |
| Kobayashi et al. ( | Patients with mild cognitive impairment. Open-label study. | Bifidobacterium breve A1 (2 × 1010 CFU/day) | Oral supplementation of B. breve A1 in participants with MCI improved cognitive function, thus suggesting the potential of B. breve A1 for improving cognitive function and maintaining quality of life in the elderly |
| Kobayashi et al. ( | Patients with mild cognitive impairment. Double-blind RCT study. | Bifidobacterium breve A1 (2 × 1010 CFU/day) | The results of the present study suggest the safety of B. breve A1 supplementation and its potential in maintaining cognitive function in elderly people with memory impairment |
Source: Own compilation based on literature review.
FIGURE 2Links between nutrition and mental health.